ClinicalTrials.gg
RecruitingNCT06649097CRYSTALUpdated Oct 28, 2025

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

An observational study in Intracranial Hemorrhage, Ventriculitis and Intracranial Abscess, sponsored by Christopher P Kellner. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Christopher P Kellner · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Intracranial Hemorrhages with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Intracranial Hemorrhages · United States.

Planned enrollment
7th of 19
250 · median 178
Started
2025
with 3 others
Observational
19 of 63
6 open now
Primary completion
2031-01
later than 19 of 20 live
Registered
53rd of 63
by date

Among the 63 studies in Intracranial Hemorrhages with a site in United States, this one is the 7th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2025, is one of 19 observational ones, reaches primary completion later than 19 of the 20 other live ones, and was the 53rd registered.

Intracranial Hemorrhages

211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.

Browse Intracranial Hemorrhages studies →

Open to participants now

17 of the 63 studies in Intracranial Hemorrhages with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Intracranial Hemorrhages studies recruiting now, 27 (63%) set no upper age limit and 5 (12%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Intracranial Hemorrhages with a site in United States, or all of them as a file.
02

Study summary

The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.

Read the detailed description

The IRRAflow system offers automated irrigation, controlled drainage, and ICP monitoring all in one system for the treatment of intracranial hemorrhage - [Intracerebral hemorrhage (ICH), Intraventricular hemorrhage (IVH), Subarachnoid hemorrhage (SAH), Subdural hematoma (SDH)], intracranial abscess, and ventriculitis.

The analysis of the IRRAS catheter will occur prospectively if it is determined the patient meets the enrollment criteria. All patients enrolled in the trial will receive additional supportive and medical treatment by choice of the treating physician and in accordance with standard of care. Such treatment includes but is not limited to neurointensive care, neuromonitoring, and surgical or endovascular occlusion of identified sources of intracranial hemorrhage (e.g. vascular anomalies, aneurysms, etc.).

03

Conditions studied

  • Intracranial Hemorrhage
  • Ventriculitis
  • Intracranial Abscess
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patient population for this study will be comprised of up to 250 patients with primary diagnosis of intracranial hemorrhage (SAH, ICH, IVH, SDH), ventriculitis, or intracranial abscess.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years of age
  • Intracranial hemorrhage documented on head CT or MRI scan.
  • Indication for active fluid exchange evaluated by treating physician.
  • Signed obtained by patient or Legal Authorized Representative
  • Scheduled enrollment and treatment within 72 hours of last known well (LKW)

Exclusion criteria

Exclusion criteria:

  • GCS ≤ 5
  • Pregnancy
  • Fixed and dilated pupil
  • Life-threatening medical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
250 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • IRRAflow device

    All patients enrolled into the study will undergo treatment with the IRRAflow device

    Device: IRRAflow® CNS (Active Fluid Exchange) System

Interventions

  • DeviceIRRAflow® CNS (Active Fluid Exchange) System

    The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.

06

What researchers measure

Primary outcomes

  1. Residual blood volume by post bleed day 5

    The residual blood volume at day 5 will be calculated to determine the efficacy of the IRRAflow system compared to other external ventricular drains (EVDs)

    Time frame: Post-procedure day 5

  2. Utility weighted modified Rankin Score

    Modified Rankin Scale score at 6 months will be collected to determine patient functional outcomes at 6 months. Scores range from 0 to 6, with 0 indicating no disability and 6 indicating death

    Time frame: End of study, at 6 months

Secondary outcomes

  1. Rate of blood clearance

    Rate of blood clearance will be calculated based on pre- and post-procedure blood volumes

    Time frame: Immediately before and after the procedure

  2. Direct hospitalization costs

    Direct hospitalization costs will be determined based on the hospital-reported cost of care for the entirety of the patient's hospital stay

    Time frame: Discharge, up to 7 days post procedure

  3. NSICU Length of Stay

    Hospital quality metrics will include length of neonatal surgery intensive care unit (NSICU) stay in days

    Time frame: Discharge, up to 7 days post procedure

  4. Hospital Length of Stay (LOS)

    Hospital quality metrics will include length of hospital stay in days

    Time frame: Discharge, up to 7 days post procedure

  5. Proportion of participants needing a shunt

    Proportion of participants needing a shunt will be calculated to determine how many patients needed a shunt to treat their hydrocephalus

    Time frame: Discharge, up to 7 days post procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. The intention will be to publish together between the principal investigator and the sponsor. Following publication, Mount Sinai will archive and store all associated data on its cloud-based system.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2031, 64 months after the start.

Of 44 non-industry observational studies under Intracranial Hemorrhages, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 130. This study's planned 64 months is close to that.

Counting every sponsor, half of 49 studies reached it within 59 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 18, 2024
StartActual
Sep 25, 2025
Primary completionEst.
Jan 2031
CompletionEst.
Jul 2031
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649097
Lead sponsor
Christopher P Kellner
Collaborators
IRRAS
Responsible party
Christopher P Kellner (Associate Professor, Neurosurgery, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Oct 18, 2024
Start date
Sep 25, 2025
Primary completion
Jan 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Oct 28, 2025

Study contacts

Sukaina Davdani
Contact
Sukaina.Davdani@mountsinai.org
(212) 241-2524
Sydney Edwards
Contact
Sydney.Edwards@mountsinai.org
(212) 241-2524
Christopher Kellner
principal investigator · Icahn School of Medicine at Mount Sinai
Nicholas Brandmeir
principal investigator · West Virginia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion